Optimal approach to potentially resectable liver metastases from colorectal cancer

被引：4

作者：

Falcone, Alfredo ^{[1
,2
]}

Fornaro, Lorenzo ^{[1
]}

Loupakis, Fotios ^{[1
]}

Masi, Gianluca ^{[1
]}

Vasile, Enrico ^{[1
]}

机构：

[1] Ist Toscano Tumori, Dept Oncol, Azienda Livorno USL6, Livorno, Italy

[2] Univ Pisa, Dept Oncol Transplants & New Technol Med, I-56100 Pisa, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2008年 / 8卷 / 10期

关键词：

D O I：

10.1586/14737140.8.10.1533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1533 / 1539

页数：7

共 51 条

[1]

Adam R, 2001, ANN SURG ONCOL, V8, P347

[2]

[Anonymous], J CLIN ONCOL S

[3] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[4]

BOKEMEYER C, 2007, J CLIN ONCOL, V25

[5] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966 [J].

Cassidy, J. ;

Cunningham, D. ;

Berry, S. R. ;

Rivera, F. ;

Clarke, S. J. ;

Kretzschmar, A. ;

Diaz-Rubio, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[6] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].

Chung, KY ;

Shia, J ;

Kemeny, NE ;

Shah, M ;

Schwartz, GK ;

Tse, A ;

Hamilton, A ;

Pan, D ;

Schrag, D ;

Schwartz, L ;

Klimstra, DS ;

Fridman, D ;

Kelsen, DP ;

Saltz, LB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810

[7] Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].

Colucci, G ;

Gebbia, V ;

Paoletti, G ;

Giuliani, F ;

Caruso, M ;

Gebbia, N ;

Carteni, G ;

Agostara, B ;

Pezzella, G ;

Manzione, L ;

Borsellino, N ;

Misino, A ;

Romito, S ;

Durini, E ;

Cordio, S ;

Di Seri, M ;

Lopez, M ;

Maiello, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875

[8] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[9] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[10] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

← 1 2 3 4 5 6 →